Anthony J. Japour M.D.

Dr. Anthony Japour brings 30 years of leadership experience as a physician and in clinical drug and diagnostic development and proven success in Commercial product launch, Lifecycle Management, Board of Directors and Coaching. He marries expertise across development, commercialization and academic research.

Dr. Japour began his career at Harvard Medical School as a molecular virologist and translational research investigator. Dr. Japour received several research grants including a National Institutes of Allergy and Infectious Diseases K11 Award and RO1 Principal Investigator grant in the area of HIV drug resistance. He has served as strategic advisor on new product evaluation and development, M&A, FDA dialogue.

In the mid-1990’s Dr. Japour moved into the biopharmaceutical industry at Abbott Laboratories where his contributions led to accelerated FDA approval for KALETRA® (lopinavir/ritonavir) indicated for adults and children with HIV-1 infection. Experience in drug development Phase I-IV clinical trials. Strong Industry contacts in academic, commercial and government. Expertly navigates FDA dialogue. Successful commercial launch of $1B drug for HIV/AIDS.

Over the years, Dr. Japour has provided strategic planning, public health policy, education and research consultation for private, public and governmental organizations. In 1996, Dr. Japour worked with colleagues at Roche Molecular Systems to launch the first commercial HIV Viral Load test which transformed the management of HIV persons globally.

Dr. Japour served as the Chief Executive Officer for AdvancedDx Biological Laboratories, USA, a next generation sequencing company with products for infectious diseases including COVID-19, HIV, CMV, and TB.

Dr. Japour has experience as an Independent Director on the Board of Directors for Opko Healthcare, Inc and he recently joined the board of directors of Sanaby Health Acquisition Corp. I.

He currently serves as CEO, President, and board director of iTolerance, a company pioneering regenerative medicine without immunosuppression.

He holds a bachelor’s degree from the University of Michigan, Ann Arbor and a medical degree from Northwestern University Fineberg School of Medicine.